Vitale N, Moss J, Vaughan M
Pulmonary-Critical Care Medicine Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Biol Chem. 1997 Feb 14;272(7):3897-904. doi: 10.1074/jbc.272.7.3897.
ADP-ribosylation factors (ARFs) are a family of approximately 20-kDa guanine nucleotide-binding proteins and members of the Ras superfamily, originally identified and purified by their ability to enhance the ADP-ribosyltransferase activity of cholera toxin and more recently recognized as critical participants in vesicular trafficking pathways and phospholipase D activation. ARD1 is a 64-kDa protein with an 18-kDa carboxyl-terminal ARF domain (p3) and a 46-kDa amino-terminal extension (p5) that is widely expressed in mammalian tissues. Using recombinant proteins, we showed that p5, the amino-terminal domain of ARD1, stimulates the GTPase activity of p3, the ARF domain, and appears to be the GTPase-activating protein (GAP) component of this bifunctional protein, whereas in other members of the Ras superfamily a separate GAP molecule interacts with the effector region of the GTP-binding protein. p5 stimulated the GTPase activity of p3 but not of ARF1, which differs from p3 in several amino acids in the effector domain. After substitution of 7 amino acids from p3 in the appropriate position in ARF1, the chimeric protein ARF1(39-45p3) bound to p5, which increased its GTPase activity. Specifically, after Gly40 and Thr45 in the putative effector domain of ARF1 were replaced with the equivalent Asp and Pro, respectively, from p3, functional interaction of the chimeric ARF1 with p5 was increased. Thus, Asp25 and Pro30 of the ARF domain (p3) of ARD1 are involved in its functional and physical interaction with the GTPase-activating (p5) domain of ARD1. After deletion of the amino-terminal 15 amino acids from ARF1(39-45p3), its interaction with p5 was essentially equivalent to that of p3, suggesting that the amino terminus of ARF1(39-45p3) may interfere with binding to p5. These results are consistent with the conclusion that the GAP domain of ARD1 interacts with the effector region of the ARF domain and thereby stimulates GTP hydrolysis.
ADP核糖基化因子(ARFs)是一类分子量约为20 kDa的鸟嘌呤核苷酸结合蛋白,属于Ras超家族成员,最初因其增强霍乱毒素ADP核糖基转移酶活性的能力而被鉴定和纯化,最近被认为是囊泡运输途径和磷脂酶D激活的关键参与者。ARD1是一种64 kDa的蛋白质,具有一个18 kDa的羧基末端ARF结构域(p3)和一个46 kDa的氨基末端延伸部分(p5),在哺乳动物组织中广泛表达。利用重组蛋白,我们发现ARD1的氨基末端结构域p5能刺激ARF结构域p3的GTP酶活性,并且似乎是这种双功能蛋白的GTP酶激活蛋白(GAP)组分,而在Ras超家族的其他成员中,一个单独的GAP分子与GTP结合蛋白的效应器区域相互作用。p5刺激了p3的GTP酶活性,但未刺激ARF1的GTP酶活性,ARF1在效应器结构域的几个氨基酸上与p3不同。在将ARF1中7个来自p3的氨基酸替换到相应位置后,嵌合蛋白ARF1(39 - 45p3)与p5结合,这增加了其GTP酶活性。具体而言,在将ARF1假定效应器结构域中的Gly40和Thr45分别替换为来自p3的等效Asp和Pro后,嵌合ARF1与p5的功能相互作用增强。因此,ARD1的ARF结构域(p3)中的Asp25和Pro30参与了其与ARD1的GTP酶激活(p5)结构域的功能和物理相互作用。从ARF1(39 - 45p3)中删除氨基末端的15个氨基酸后,其与p5的相互作用基本上与p3相同,这表明ARF1(39 - 45p3)的氨基末端可能会干扰与p5的结合。这些结果与ARD1的GAP结构域与ARF结构域的效应器区域相互作用从而刺激GTP水解的结论一致。